Elanco Animal Health (ELAN) Consolidated Net Income (2017 - 2026)
Elanco Animal Health (ELAN) posted Consolidated Net Income of $57.0 million for Q1 2026, up 120.65% sequentially from -$276.0 million in Q4 2025, and down 14.93% YoY from $67.0 million in Q1 2025.
Elanco Animal Health (ELAN) Consolidated Net Income (2017 - 2026) Analysis & Trends
Elanco Animal Health has reported Consolidated Net Income for 10 years, with the latest figure at $57.0 million in Q1 2026.
- Quarterly Consolidated Net Income fell 14.93% year-over-year to $57.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$242.0 million (down 164.88% YoY) and the FY2025 annual result came in at -$232.0 million, down 168.64% from the prior year.
- Consolidated Net Income advanced to $57.0 million in Q1 2026 per ELAN's latest filing, from -$276.0 million in the prior quarter.
- Over five years, Consolidated Net Income peaked at $364.0 million in Q3 2024 and troughed at -$1.1 billion in Q3 2023.
- A 5-year average of -$67.4 million and a median of -$10.0 million in 2022 frame the typical range for Consolidated Net Income.
- The sharpest annual moves came in 2022 and 2025: Consolidated Net Income jumped 179.69% in 2022, then sank 3350.0% in 2025.
- Over 5 years, Consolidated Net Income stood at -$54.0 million in 2022, then slumped by 161.11% to -$141.0 million in 2023, then soared by 94.33% to -$8.0 million in 2024, then tumbled by 3350.0% to -$276.0 million in 2025, then jumped by 120.65% to $57.0 million in 2026.
- According to Business Quant data, Consolidated Net Income over the past three periods registered $57.0 million, -$276.0 million, and -$34.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.96 Bn | 43.00 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.23 Bn | 39.58 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.76 Bn | 30.08 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn | 1.33 Bn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.69 Bn | 17.81 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 11.78 Bn | 11.25 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | Alkermes | 8.14 Bn | 7.48 Bn | 397.90 Mn | 524,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 54.00 Mn |
| Mar 31, 2026 | 57.00 Mn |
| Dec 31, 2025 | -276.00 Mn |
| Sep 30, 2025 | -34.00 Mn |
| Jun 30, 2025 | 11.00 Mn |
| Mar 31, 2025 | 67.00 Mn |
| Dec 31, 2024 | -8.00 Mn |
| Sep 30, 2024 | 364.00 Mn |
| Jun 30, 2024 | -50.00 Mn |
| Mar 31, 2024 | 32.00 Mn |
| Dec 31, 2023 | -141.00 Mn |
| Sep 30, 2023 | -1.10 Bn |
| Jun 30, 2023 | -97.00 Mn |
| Mar 31, 2023 | 103.00 Mn |
| Dec 31, 2022 | -54.00 Mn |
| Sep 30, 2022 | -65.00 Mn |
| Jun 30, 2022 | -10.00 Mn |
| Mar 31, 2022 | 51.00 Mn |
| Dec 31, 2021 | -105.00 Mn |
| Sep 30, 2021 | -108.00 Mn |